The company’s consistent all-around performance was a major factor in the decision to buy shares in March 2018, and it’s a big reason why we have chosen to nearly double our stake in the company.
This is a high-quality company that has positioned itself very well to take advantage of a number of major trends in healthcare. Excellent fundamentals, a 3%+ yield, a moderate payout ratio, almost a decade of dividend raises, double-digit long-term dividend growth, and the potential that shares are 26% undervalued are all reasons why dividend growth investors should take a strong look at this stock.
It will be the 33rd purchase in our Income Builder Portfolio.
It has a 16-year streak of raising its dividend, its yield is approaching 5%, it has a fast dividend growth rate, and it has good quality rankings. On top of all of this, it appears 6% undervalued right now.
This company runs a very simple business model that provides a necessary and ubiquitous service to millions of people. With a 5%+ yield, a reasonable payout ratio, almost 20 consecutive years of dividend raises, and the potential that shares are 9% undervalued, this is a rare high-yield dividend growth stock that looks undervalued in today’s market.
With 25 consecutive years of dividend raises, double-digit long-term dividend growth, a very low payout ratio, a yield near 2%, and the possibility that shares are 55% undervalued, this could be one of the most undervalued dividend growth stocks in the world.
This stock seems like a very attractive dividend growth opportunity right now. Not only does it yield 5%, but it has a top-tier Dividend Safety rating and a proven propensity for increasing its dividend. On top of all of this, shares appear 20% undervalued at recent prices.
This is a high-quality company with excellent fundamentals across the board. More than 40 consecutive years of dividend increases, a 3%+ yield, double-digit long-term dividend growth, a low payout ratio, and the potential that shares are 18% undervalued are all great reasons to consider this stock right now.
This is a high-quality company with excellent fundamentals. Its diversification, depth, and breadth in terms of the geographic exposure, industry mix, and client base is incredible. The stock offers a ~3.5% yield, payout ratio below 50%, and 10 consecutive years of dividend raises. With shares potentially 13% undervalued, dividend growth investors should take a good look at this compelling long-term investment opportunity.
Welcome back to the Valuation Zone, and our fourth well-valued dividend growth stock for 2019.
